Archives of Pathology & Laboratory Medicine · 2001 · 76 citations · 27 references
Life SciencesInfectious DiseasesMicrobiologyBacteriologyDiagnostic MicrobiologyMedical MicrobiologyDiagnostic BacteriologyInfectious Disease Molecular TestingMycobacterial DiagnosticsNucleic Acid Amplification TestingTuberculosis DiagnosisTuberculosis Diagnostic TestingClinical Utility AnalysisClinical Utility AssessmentDirect DetectionMycobacterial DiagnosisNucleic Acid AmplificationNucleic Acid Amplification DiagnosticsTuberculosis DiagnosticsTuberculosis Molecular Testing
Abstract Objective.—To assess the clinical utility of the commercial nucleic acid amplification (NAA) tests (ie, Amplified Mycobacterium Tuberculosis Direct Test, Gen-Probe, Inc and AMPLICOR Mycobacterium tuberculosis Test, Roche Molecular Systems, Inc) for direct detection of Mycobacterium tuberculosis complex. Data Sources.—Review of the English-language literature. Conclusions.—The performance of both NAA tests is excellent (sensitivity, ≥95%; specificity, 100%) when testing respiratory specimens that are smear-positive for acid-fast bacilli (AFB). Only the Gen-Probe assay is approved for testing respiratory specimens regardless of the AFB smear result. Data from 3 studies showed that the sensitivity of the Mycobacterium Tuberculosis Direct Test in smear-negative patients ranged from 83% to 85%, and that the specificity was 99%. Both NAA tests have been used to test nonrespiratory specimens; in some studies, the performance was comparable to the performance obtained for respiratory specimens, whereas i...
27
The resurgence of tuberculosis: is your laboratory ready?
Fred C. Tenover, Jack T. Crawford, Robin Huebner et al. · Journal of Clinical Microbiology · 1993 · 377 citations · Full text
Chiyoji Abe, Ken‐ichi Hirano, Masako Wada et al. · Journal of Clinical Microbiology · 1993 · 204 citations · Full text